Shanghai Pharmaceuticals (02607) said its net profit attributable to equity holders for the six months ended 30 June 2016 rose 12.94% year-on-year to Rmb1,732 million.
Basic and diluted earnings per share were Rmb64.43 cents.
Operating revenue was Rmb59,695 million, an increase of 17.16% from a year earlier.
No interim dividend will be distributed.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
